Description
Springer Guidelines for the Use of Psychotropic Drugs A Clinical Handbook 1st Editon 2012 Softbound by H.C. Stancer, P.E. Garfinkel, V.M. Rakoff
. . . to the Clinician Although huge quantities of drugs are dispensed daily by psychiatrists, there appears to be insufficient concern about the short and long term effects of these exogenous agents on the recipients - our patients. Many clinicians have been trained at a time when knowledge of clinical psychopharmacology was super ficial at best, and recent trainees do not necessarily have access to newer, con stantly changing, relevant information. The busy clinician is frequently depen dent upon the limited knowledge dispensed by the drug company representatives and naturally shys away from many of the more esoteric contributions appearing in the literature. Because of the foregoing issues, the Executive of the Clarke Institute of Psychiatry of the University of Toronto, with the financial support of the Ministry of Health of the Government of Ontario, organized an inter national symposium on May 14-17, 1982, to bring together some of the acknowledged experts in clinical psychopharmacology. This book is, in part, a reflection of that symposium. The editors are aware that a contributed volume, however tightly edited, is not necessarily a textbook. Notwithstanding this, it was thought to be important to assemble expert opinion on current important issues, of immediate concern to the practicing clinician. With this in mind, the chapters have been organized around five themes. Schizophrenia, Affective disorders, and Anxiety, are clearly important since they are the major targets of drug use in psychiatry. Section I. Affective Disorders: Hints for Clinicians.- 1 Summary of the Guidelines for Use of Antidepressants and Lithium.- 2 Use of Antidepressants in the Geriatric Population.- 3 The Use of Antidepressant Medication in Children and Adolescents.- 4 Mechanisms and Interventions in Tricyclic Antidepressant Overdoses.- 5 Recent Developments Regarding the Use of Monoamine Oxidase Inhibitors in Psychopharmacology.- 6 Lithium in Prophylaxis and Maintenance of Affective Disorders.- 7 Somatic Side Effects of Long-Term Lithium Treatment.- 8 Clinical Pharmacokinetics of Antidepressants.- Section II. Schizophrenia: Hints for Clinicians.- 9 Summary of Guidelines for the Use of Psychotropic Drugs in the Treatment of Schizophrenia.- 10 Antipsychotics in the Maintenance Treatment of Schizophrenia.- 11 Clinical Applications of Drug Studies.- 12 Tardive Dyskinesia: Management and New Treatment.- 13 New Clinical Concepts on Neuroleptic-Induced Supersensitivity Disorders: Tardive Dyskinesia and Supersensitivity Psychosis.- 14 The Implications of Cerebral Ventricular Size for Neuroleptic Therapy of Schizophrenia.- 15 Clinical Significance of Neuroleptic Plasma Levels.- 16 The Clinical Utility of Plasma Neuroleptic Levels.- 17 Neuroregulators and Schizophrenia: A Look at the Dopamine and Endorphin Hypotheses.- 18 Future Research Directions in the Treatment of Schizophrenia.- Section III. Anxiety: Hints for Clinicians.- 19 Summary of the Guidelines for the Use of Psychotropic Drugs in the Treatment of Anxiety.- 20 The Efficacy and Safety of Drugs to Treat Anxiety.- 21 Clinical Trial Methodology: Issues for the Psychopharmacologie Treatment of the Anxiety Disorders.- 22 Pharmacokinetics and Drug Concentration Measurement: Relevance to Treatment of Anxiety Disorders.- Section IV. Emergency Psychiatry: Hints for Clinicians.- 23 Summary of the Guidelines for the Use of Psychotropic Drugs in Emergency Psychiatry.- 24 Rapid Neuroleptization: Origins and Future Developments.- 25 Sedatives in the Management of Psychiatric Emergencies.- 26 Rapid Treatment of Psychosis.- 27 Assessment of Psychotropic Drugs Following Acute Doses: Pharmacodynamics and Pharmacokinetics.- Section V. Forensic Psychiatry: Hints for Clinicians.- 28 Summary of the Guidelines for the Use of Psychiatric Drugs in Forensic Psychiatry.- 29 Review of Research on the Use of Drugs to Control Violent Behavior.- 30 Review of Research into the Use of Drugs and the Treatment of Sexual Deviations with Special Reference to the Use of Cyproterone Acetate (Androcur).- 31 Antiandrogenic Treatment of the Paraphilias.- 32 Limitation and Alternatives to the Use of Drugs in Violent Patients.